# QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer

> **NCT06951997** · PHASE2 · RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 33 (estimated)

## Conditions studied

- Metastatic Pancreatic Cancer

## Interventions

- **DRUG:** QL1706
- **DRUG:** Chidamide
- **DRUG:** Gemcitabine
- **DRUG:** Nab-paclitaxel

## Key facts

- **NCT ID:** NCT06951997
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-07
- **Primary completion:** 2027-05-15
- **Final completion:** 2027-12-31
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2026-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06951997

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06951997, "QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT06951997. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*